Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 970 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Terminated Phase 2 Interventional Results available

Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

NCT05636852
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Altropane (123I) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 13, 2026, 5:07 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07711418
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Oxnard, California • Palmdale, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

NCT02465268
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions
pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 13, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Telehealth-Enhanced Asthma Care for Home After the Emergency Room

NCT05844891
View directory record Official record
Conditions
Asthma in Children
Interventions
Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER), Enhanced Care (EC)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 12 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Secretome Treatment for Facial Rejuvenation

NCT07227883
View directory record Official record
Conditions
Facial Aging, Rejuvenation, Stem Cell, Stem Cell Banking
Interventions
Autologous Hair Follicle-Derived Secretome, Control Saline
Other
Lead sponsor
Acorn Biolabs Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

NCT04278924
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Placebo, TAK-079
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nurses Taking On Readiness Measures - Mercer County, New Jersey

NCT05455580
View directory record Official record
Conditions
Disaster, Vulnerable Populations
Interventions
Nurses Taking On Readiness Measures (N-TORM)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Utilizing Protein During Weight Loss to Impact Physical Function and Bone

NCT03819478
View directory record Official record
Conditions
Obesity, Weight Loss, Diet Modification, Aging, Weight Change, Body, Dietary Habits, Osteopenia, Osteoporosis, Bone Loss, Fractures, Bone
Interventions
Weight loss intervention months 0-6, Exercise intervention months 0-6, NutraBio™ CarboMax Supplement, 6-month NutraBio™ 100% Whey Protein Isolate Supplement, 18-month NutraBio™ 100% Whey Protein Isolate Supplement
Behavioral · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis

NCT02029040
View directory record Official record
Conditions
Acute Bronchiolitis
Interventions
3% Hypertonic Saline, 0.9 % normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 12 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

NCT02409459
View directory record Official record
Conditions
Iron Deficiency, Fibromyalgia
Interventions
Injectafer, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Copper IUD Treatment Observation Study

NCT02519231
View directory record Official record
Conditions
Menorrhagia
Interventions
Naproxen, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery

NCT04081545
View directory record Official record
Conditions
Opioid Use, Unspecified, Bariatric Surgery Candidate, Anesthesia
Interventions
Opioid Anesthetics, Non Opioid Analgesics
Drug
Lead sponsor
Christine Oryhan
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 13, 2026, 5:07 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Machine Learning Technology in Predicting Relapse and Implementing Peer Recovery Intervention Before Drug Use Occurs

NCT05976672
View directory record Official record
Conditions
Substance Abuse Disorder
Interventions
PRSS (Peer Recovery Support Specialist)
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

NCT00597818
View directory record Official record
Conditions
NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions
Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Microvascular Coronary Disease In Women: Impact Of Ranolazine

NCT00570089
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 13, 2026, 5:07 AM EDT
Recruiting Phase 1 Interventional

Levothyroxine Supplementation for Heart Transplant Recipients

NCT06428097
View directory record Official record
Conditions
Heart Transplant Failure, Heart Transplant Infection
Interventions
Levothyroxine, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Recruiting Phase 4 Interventional

Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery

NCT06949826
View directory record Official record
Conditions
Pain, Postoperative, Ankle Fracture Surgery, Opioid Use Disorder, Opioid Dependence, Opioid Analgesia
Interventions
Buprenorphine Transdermal System, Placebo Patch
Drug
Lead sponsor
Jenna-Leigh Wilson
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Cannabichromene Safety in Rheumatoid Arthritis

NCT07087938
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Cannabichromene
Drug
Lead sponsor
Crystal Lederhos Smith
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

NCT01596725
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 13, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

NCT00825916
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 13, 2026, 5:07 AM EDT